Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

Université du Québec à Montréal

$69,317.00

Carboxymethyl starch: biocompatible carrier for controlled release of artemisinin and peschiera fuschiaefolia antimalaria combination

EF 2016-17

Résumé
Malaria, an infectious disease, is still one of the major causes of mortality. In 2010, the World Health Organization (WHO) has estimated about 219 million cases of malaria and up to 1.2 million deaths, mostly among children in Africa. Karici Diagnostics, a Canadian company specialized in diagnostic and treatment of infectious diseases, developed antimalaria natural agents extracted from plant Peschiera fuschiaefolia (Pf). Recently, Karici Diagnostic approached the Artemisinin combination therapy, answering to a need of the WHO, and advanced the hypothesis that the association of Pf and Artemisinin can improve the antimalarial activity, particularly for multidrug resistant strains. Exciting experimental in vitro data were often followed by disappointing in vivo results because of the insufficient concentration of drug due to poor water solubility, low absorption and undesirable accumulation often with harmful side effects. To overcome these problems, Karici Diagnostic investigated in collaboration with UQ?M the development of suitable drug carrier system. This system is mainly based on a starch derivative used as support to protect these bioactive agents during stomach transit and to transport them at the absorption sites. The technology concept consists in adding carboxyl groups onto the starch chain in order to promote the formation of a compact gel-like structure expected to be mechanically stable in acidic biological medium. This biomaterial is novel for pharmaceutical sustained release forms. Since the proposed antimalarial agents are natural and their association is novel, there are not standard methods to measure these bioactive agents. For this reason, the challenges in the present project concern not only the development of suitable carriers, but also to propose new analytical methods to quantitatively determine the active Pf alone and the Artemisinin/Pf combination. In addition to the economic benefits for the partner company, the present project also enables the formation of highly qualified personel and students training making their knowledge more relevant to their future professional career.
Programme
Collaborative Research and Development Grants
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
455094-2013
Name nom
Mateescu, MirceaAlexandru
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2013
Award amount
69317
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1208
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Materials sciences
Area of application fr
Sciences des matériaux
Research subject code
3754
Research subject group en
Polymer chemistry
Research subject group fr
Chimie des polymères
Research subject en
Biopolymers
Research subject fr
Biopolymères
Partie
3
Nb partie
3
Application title
Carboxymethyl starch: biocompatible carrier for controlled release of artemisinin and peschiera fuschiaefolia antimalaria combination
Keyword
NSERC
Application summary
Malaria, an infectious disease, is still one of the major causes of mortality. In 2010, the World Health Organization (WHO) has estimated about 219 million cases of malaria and up to 1.2 million deaths, mostly among children in Africa. Karici Diagnostics, a Canadian company specialized in diagnostic and treatment of infectious diseases, developed antimalaria natural agents extracted from plant Peschiera fuschiaefolia (Pf). Recently, Karici Diagnostic approached the Artemisinin combination therapy, answering to a need of the WHO, and advanced the hypothesis that the association of Pf and Artemisinin can improve the antimalarial activity, particularly for multidrug resistant strains. Exciting experimental in vitro data were often followed by disappointing in vivo results because of the insufficient concentration of drug due to poor water solubility, low absorption and undesirable accumulation often with harmful side effects. To overcome these problems, Karici Diagnostic investigated in collaboration with UQ?M the development of suitable drug carrier system. This system is mainly based on a starch derivative used as support to protect these bioactive agents during stomach transit and to transport them at the absorption sites. The technology concept consists in adding carboxyl groups onto the starch chain in order to promote the formation of a compact gel-like structure expected to be mechanically stable in acidic biological medium. This biomaterial is novel for pharmaceutical sustained release forms. Since the proposed antimalarial agents are natural and their association is novel, there are not standard methods to measure these bioactive agents. For this reason, the challenges in the present project concern not only the development of suitable carriers, but also to propose new analytical methods to quantitatively determine the active Pf alone and the Artemisinin/Pf combination. In addition to the economic benefits for the partner company, the present project also enables the formation of highly qualified personel and students training making their knowledge more relevant to their future professional career.